Thus, we propose that the REDD1–NF-κB axis is the molecular link between obesity-related inflammation and insulin resistance and should be targeted in therapeutic strategies to normalize body weight and improve metabolic complications. This evidence concerns the gene NFKB1 and Insulin resistance.